The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million
Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in support of FDA discussion; Jaguar to explore possible approval pathway for crofelemer in breast and lung cancer based on phase 3 results
Jaguar planning to begin commercial launch in October 2024 for Gelclair®, the company's third prescription product
Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure
REMINDER: Jaguar to host investor webcast Tuesday, August 13th at 8:30 a.m. Eastern regarding Q2 2024 financials and company updates; Click here to register for webcast
Read MoreJaguar to explore approval pathway for crofelemer in breast and lung cancer based on phase 3 results
Click here to register for investor webcast
Company plans to file its Earnings Report on August 13, 2024 on Form 10-Q for the quarter ended June 30, 2024
Read MoreClinical Trial Collaboration Follows 510(k) Submission and Passing of FDA Administrative Review; Preludes Planned International Launch for the mBȏs TKA System
Strategic Partner Shalby is Recognized as one of the Leading Institutions for Orthopedic Surgeries Worldwide, Performing Over 14,000 Annual Knee Replacement Surgeries Globally
Read More
Exclusive licensing of 10 invention patents and patent applications surrounding gas sensor and medical devices
All-stock licensing structure aligns the licensor's long-term interest with Ainos shareholders'
Read MoreApplication was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive Review
FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested
Read More- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients
- Dermata continues discussions with potential botulinum toxin partners for DMT410
- Raised $2.3 million in net proceeds from financing completed in 2Q 2024
Read MoreIn 2022 breast cancer was the most common cancer in women in 157 countries out of 185, and lung cancer is the most common cancer worldwide.1 Click here to register for webcast.
Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi of crofelemer in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure
Read MoreDr. Elisabetsky is also an advisor to Magdalena Biosciences, the joint venture formed by Jaguar and Filament Health focused on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions
As announced, Jaguar recently executed an out-license deal with Magdalena Biosciences for a botanical drug candidate for possible schizophrenia and psychoses indications and for development with potential corporate partners; the global schizophrenia treatment market valued at $8.29 billion
Read MoreIt is estimated that 10-15% of people in the United States have IBS
Read MoreReports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)
Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billion
Received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in June
Announced positive Phase 3 data for combination vaccine against influenza and COVID-19
Announced positive Phase 3 data for next-generation COVID-19 vaccine
Read MoreNew patent issued for core rare disease target indication for crofelemer
Jaguar has approximately 200 patents issued and pending
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome (SBS) and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with proof-of-concept results expected before the end of 2024 and throughout 2025
Read MoreGerman Distributor placed six-figure initial order that is expected to ship in the third quarter of 2024
Germany is the largest fitness market after the United States
Germany's largest fitness company, RSG Group, owns Gold's Gym and McFIT among other brands
